Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.
Fiscal year to December 2025, from the company's annual filing with the SEC.
| Salesyearly sales | $7.9B |
| Sales growthchange from the year before | +12.7% |
| Gross marginshare of sales left after the direct cost of what it sells | 31.4% |
| Operating marginshare of sales left after running the business | 7.0% |
| Net marginshare of sales kept as profit | 3.8% |
| Free-cash-flow marginspare cash generated per $100 of sales | 8.4% |
| Return on invested capitalprofit made on each $100 put into the business | 7.1% |
| Return on equityprofit vs. shareholders' accounting value | 8.9% |
| Debt / equitydebt vs. shareholders' accounting value | 0.81 |
| Change in share countnegative = the company is buying back its shares | +3.5% |
2 insiders sold $26.4M (all under pre-arranged plans) on the open market.
| Ashken Ian G HDirector | Sold (plan)Aug 4 | 85,072 shat $40.36 · $3.4M |
| Ashken Ian G HDirector | Sold (plan)Aug 3 | 214,928 shat $39.91 · $8.6M |
| Lillie James EDirector | Sold (plan)Aug 3 | 360,000 shat $39.84 · $14.3M |
From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.
Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy